Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Soleno Therapeutics (SLNO) Share-based Compensation (2016 - 2025)

Soleno Therapeutics (SLNO) has disclosed Share-based Compensation for 9 consecutive years, with $44.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Share-based Compensation changed N/A to $44.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $79.1 million, a N/A change, with the full-year FY2025 number at $45.8 million, down 54.13% from a year prior.
  • Share-based Compensation was $44.7 million for Q4 2025 at Soleno Therapeutics, up from $10.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $44.7 million in Q4 2025 to a low of $9.7 million in Q2 2025.